M&A isn’t just for big pharma. Mid-size companies are stepping up deal hunts

The biopharma sector is experiencing a surge in mergers and acquisitions, with mid-sized companies taking a more prominent role in the market. This shift includes American mid-cap drugmakers and European foundation-governed firms actively pursuing deals, indicating a broader trend beyond the traditional dominance of large pharmaceutical companies. As the landscape evolves, these mid-size players are reshaping the competitive dynamics of the industry.